The Treatment Effect of Plantago Major on Lung Cancer Based on the Computed Tomography and Pathological Findings: A Case Report Study Saade Abdalkareem Jasim, Bashar Mudhaffar Abdullah, Patricio Yánez-Moretta, Wesam R. Kadhum, Yasser Fakri Mustafa, et al. Frontiers in Biomedical Technologies, 2025 Purpose: Plantago Major (PM) is widely used for the treatment of different diseases due to several active compounds. Previous studies demonstrated the treatment effect of this plant on lung cancer cell lines. Here, we introduced a patient having lung cancer proved by Computed Tomography (CT) and pathological findings. The treatment effect of PM was assessed and presented based on CT and laboratory examinations for this patient as a first human case study.Materials and Methods: A 64-year-old woman, with gastrointestinal bleeding as well as high Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) levels, was examined by the chest CT scan for suspicious lung cancer. Pathological findings confirmed the non-small cell lung cancer (adenocarcinoma, stage IIA). The patient consumed 150 ml of PM seeds extract (3-4 times daily) orally for about 4 months. Follow-up CT and laboratory examinations were performed after the treatment period to assess the effect of PM.Results: The volume of the tumor was reduced by about 62% (based on CT imaging findings) after the treatment with PM. In addition, the laboratory examinations illustrate that ESR and CRP levels reduced remarkably (from 97 mm/h to 24 mm/h for ESR; from 36.8 mg/L to 1.2 mg/L for CRP) after the treatment.Conclusion: Based on our human study, PM, as a natural compound with antioxidant, anti-inflammatory, and antibiotic characteristics, could have an anti-proliferative effect on non-small cell lung cancer. However, more follow-up examinations on big sample sizes are needed to assess the treatment effect of PM.
Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease Nava Yugavathy, Bashar Mudhaffar Abdullah, Soo Kun Lim, Abdul Halim Bin Abdul Gafor, Muh Geot Wong, et al. Current Issues in Molecular Biology, 2023 The study of anaemia is a well-developed discipline where the concepts of precision medicine have, in part, been researched extensively. This review discusses the treatment of erythropoietin (EPO) deficiency anaemia and resistance in cases of chronic kidney disease (CKD). Traditionally, erythropoietin-stimulating agents (ESAs) and iron supplementation have been used to manage anaemia in cases of CKD. However, these treatments pose potential risks, including cardiovascular and thromboembolic events. Newer treatments have emerged to address these risks, such as slow-release and low-dosage intravenous iron, oral iron supplementation, and erythropoietin–iron combination therapy. Another novel approach is the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This review highlights the need for precision medicine targeting the genetic components of EPO deficiency anaemia in CKD and discusses individual variability in genes such as the erythropoietin gene (EPO), the interleukin-β gene (IL-β), and the hypoxia-inducible factor gene (HIF). Pharmacogenetic testing aims to provide targeted therapies and interventions that are tailored to the specific characteristics of an individual, thus optimising treatment outcomes and minimising resistance and adverse effects. This article concludes by suggesting that receptor modification has the potential to revolutionise the treatment outcomes of patients with erythropoietin deficiency anaemia through the integration of the mentioned approach.
Genetic Markers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease Sangeetha Perumalsamy, Hasniza Zaman Huri, Bashar Mudhaffar Abdullah, Othman Mazlan, Wan Azman Wan Ahmad, et al. Metabolites, 2023 Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion on a background of insulin resistance (IR). IR and T2DM are associated with atherosclerotic coronary artery disease (CAD). The mechanisms of IR and atherosclerosis are known to share similar genetic and environmental roots. Endothelial dysfunction (ED) detected at the earliest stages of IR might be the origin of atherosclerosis progression. ED influences the secretion of pro-inflammatory cytokines and their encoding genes. The genes and their single nucleotide polymorphisms (SNPs) act as potential genetic markers of IR and atherosclerosis. This review focuses on the link between IR, T2DM, atherosclerosis, CAD, and the potential genetic markers CHI3L1, CD36, LEPR, RETN, IL-18, RBP-4, and RARRES2 genes.
Spectrophotometric Determination of Trace Quantities of Pure Atropine and Pharmaceutical Preparations with SbI42− Ion Riyadh Hasan Mohammed Ali, Bashar Mudhaffar Abdullah, Rasha Ismail Ahmed Indonesian Journal of Chemistry, 2023 This study aims to estimate a simple, rapid and sensitive method for a trace amount of atropine (ATR) in medicinal compounds. Two approaches were followed to accomplish this aim, i.e., spectrophotometric determination of pure ATR and pharmaceutical preparations using SbI42− ion as a new reagent. The procedure involves the implementation of an ion-association complex with this alkaloid. The resulting complex was extracted and detected spectrophotometrically at 492 nm. Appropriate parameters were investigated, including the ion SbI42− concentration and the pH value of the complex formation. Using chloroform to extract the complex, taking into consideration extraction time and volume of solvent used. The calibration graph is linear in the ranges of 0.5–5.0 × 10−3 M. Precision, accuracy, detection limit, and RSD %, as well as relative standard deviation (n = 5), were calculated. The test sensitivity was 0.013 µg cm−2. Several interference additives were studied by investigating the effect of equal and duplicate quantities of some common excipients on selectivity, such as starch, glucose, lactose, glycerin, and talc. The molar ratio of the SbI42−_ATR was determined. The amount of ATR in the pharmaceutical tablets and eye drop preparation was calculated using Erel at ratios of 2.24 and 2.75%, respectively.
Glycemic effects of simvastatin: Where do we stand? Nor Razida Razali, Hasniza Zaman Huri, Luqman Ibrahim, Shireene Ratna Vethakkan, Bashar Mudhaffar Abdullah Brazilian Journal of Pharmaceutical Sciences, 2018 In clinical practice, simvastatin is usually used in the treatment of dyslipidemia patients and those at risk of or with established cardiovascular disease. However, previous studies have shown that simvastatin has the potential to affect glycemic parameters as it reportedly reduced insulin secretion and sensitivity. The exact mechanism by which simvastatin affects glycemia is still unknown, but previous studies have postulated the involvement of the glucose-insulin secretion mechanism. This review focuses on the effects of simvastatin, either alone or in combination with other lipid lowering agents, antidiabetics and antihypertensives, on glucose homeostasis. Some studies have reported that simvastatin might impair the levels of glucose metabolism markers in the blood while others have reported no effect or improvement in glycemia.
A study on cloning and expression of HIV-1 NEF protein in HEK 293 cells by transient transfection Research Journal of Pharmaceutical Biological and Chemical Sciences, 2016
